Recruiting
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
NCT07341191· Phase 2· Canadian Cancer Trials Group· Source
Contact: Amaris Balitsky
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
NCT06880523· Phase 2· Canadian Cancer Trials Group· Source
Contact: Shivani Dadwal
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Sebastien J. Hotte (principal investigator)
Recruiting
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461· Phase 2· Canadian Cancer Trials Group· Source
Contact: Baskoro (Adi) Kartolo
Recruiting
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
NCT06641791· Phase 3· Canadian Cancer Trials Group· Source
Contact: James R. Wright
Recruiting
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
NCT06358469· Canadian Cancer Trials Group· Source
Contact: Andra Nica
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: Alejandro Garcia-Horton (principal investigator)
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Courtney Coschi (principal investigator)
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Alejandro Garcia-Horton (principal investigator)
Recruiting
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06182774· Phase 3· Canadian Cancer Trials Group· Source
Contact: Hira Mian
Recruiting
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
NCT05601440· Phase 2· Canadian Cancer Trials Group· Source
Contact: Nidhi Kumar Tyagi
Recruiting
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004· Phase 3· Canadian Cancer Trials Group· Source
Contact: Nhu Tram A. Nguyen (principal investigator)
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· Phase 2· Canadian Cancer Trials Group· Source
Contact: Clare Reade
Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
NCT05180097· Phase 2· Canadian Cancer Trials Group· Source
Contact: Amaris Balitsky
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Shivani Dadwal (principal investigator)
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
NCT04176848· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167· Phase 2/3· Canadian Cancer Trials Group· Source
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
NCT03784755· Canadian Cancer Trials Group· Source
Active, not recruiting
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
NCT03624543· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391· Phase 3· Canadian Cancer Trials Group· Source
Active, not recruiting
Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT03385655· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
NCT03410615· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Active, not recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· Phase 3· NRG Oncology· Source
Active, not recruiting
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013· Phase 3· Canadian Cancer Trials Group· Source
Contact: Elaine McWhirter
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Economic Analysis of Alliance A041202 CLL Study
NCT02414022· Canadian Cancer Trials Group· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT01841736· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
NCT01849263· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396408· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499· Phase 2· National Cancer Institute (NCI)· Source